Clinical Trials Logo

Thrombocytopenia clinical trials

View clinical trials related to Thrombocytopenia.

Filter by:

NCT ID: NCT04371939 Recruiting - Clinical trials for Wiskott-Aldrich Syndrome

Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

Start date: November 5, 2019
Phase: Phase 2
Study type: Interventional

This is a prospective, open-label, randomized, two-arm clinical trial conducted to evaluate the safety and efficacy of romiplostim in comparison with eltrombopag in the treatment of thrombocytopenia in patients with Wiskott-Aldrich syndrome

NCT ID: NCT04368598 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

A single-arm, open-label study to evaluate the efficacy and safety of Acetylcysteine plus high-dose Dexamethasone in adults newly diagnosed with primary immune thrombocytopenia (ITP).

NCT ID: NCT04226950 Recruiting - Clinical trials for Essential Thrombocytopenia

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Start date: January 10, 2020
Phase: Phase 2
Study type: Interventional

Objectives: To compare the efficacy and safety in childhood and adolescent patients (<20 years) diagnosed as essential thrombocythemia treated with the Pegylated Interferon Alfa-2b vs. Interferon Alfa. Study Design: A prospective, open-label, nonrandomized, single-center clinical trial

NCT ID: NCT04099966 Recruiting - Sickle Cell Disease Clinical Trials

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

NCT ID: NCT04005638 Recruiting - Clinical trials for Immune Thrombocytopenia

Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia

BIOCAI
Start date: February 2, 2019
Phase:
Study type: Observational

The Internal Medicine Department of Haut-Lévêque Hospital (Pr E LAZARO, Pr JL PELLEGRIN, Pr JF VIALLARD) was accredited in 2017 by the Ministry of Health as a Constitutive Reference Center for Autoimmune Cytopenia. The investigators wish to launch new research projects in autoimmune cytopenia and propose a translational and fundamental research based on collaboration between the clinical department, the biological resource center and the CNRS and INSERM research units ("Bedside to the Bench Strategy"). Thus, in the perspective of future research work, it seems imperative to set up a biological bank for the patients followed in our Reference Center.

NCT ID: NCT04003220 Recruiting - Clinical trials for Myelodysplastic Syndromes

Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker

ICTUS
Start date: September 7, 2020
Phase:
Study type: Observational

It is a translational research study with mechanistical objectives and including biological samples of patients with thrombocytopenia

NCT ID: NCT03998982 Recruiting - Clinical trials for Immune Thrombocytopenia

Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP

Start date: June 25, 2019
Phase: Phase 4
Study type: Interventional

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of glycyrrhetinic acid combining with high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

NCT ID: NCT03998059 Recruiting - Thrombocytopenia Clinical Trials

Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients

Start date: January 23, 2019
Phase:
Study type: Observational

Evaluation of immune status before and after splenectomy in immune thrombocytopenia patients.

NCT ID: NCT03975361 Recruiting - Clinical trials for Systemic Lupus Erythematosus (SLE)

Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)

ITP&SLE
Start date: April 29, 2021
Phase: N/A
Study type: Interventional

The aim of this proposal is to test if anti-BAFF antibody can restore a normal threshold of tolerance in patients in two auto-immune diseases along the RITUX-PLUS study in immune thrombocytopenia, and along the Believe study in SLE. This work would help to conclude whether or not the 'double hit' therapy may help to reset the immune system toward a more tolerogenic profile. The aim is to compare the polyreactivity and autoreactivity, of immature (central tolerance) and naïve B cells (peripheral tolerance) in the peripheral blood along the RITUX-PLUS STUDY and the BLISS BELIEVE study after treatment (B-cell reconstitution time).

NCT ID: NCT03951623 Recruiting - Clinical trials for Immune Thrombocytopenia (ITP)

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

Start date: August 12, 2019
Phase: Phase 1
Study type: Interventional

This is a randomized, double blinded, placebo-controlled phase Ib clinical trial in adult patients with immune thrombocytopenia. Cross-over treatment will be allowed during the study.